Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn

Executive Summary

Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.

Advertisement

Related Content

Relvar/Breo “Real World” Asthma Benefits Help GSK – But Can't Remove Generic Threat
Advair Generic Approval Uncertain Despite US FDA Denial Of Sandoz Petition
Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Stockwatch: Flat Is The New Black For Lilly And Sanofi
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
GSK US Pharma President Jack Bailey On A “Dynamic” 2017
Advair: A Big Generic Opportunity And A Big Question Mark In 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel